Clinical Trial Update: Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating intravenously administered pegylated liposomal mitomycin-C lipid-based prodrug (PROMITIL) in cancer patients with solid tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Promitil

Snippet

Sponsor: Lipomedix Pharmaceuticals Inc. | Conditions: Cancer, Solid Tumor | Phase 1 | Status: COMPLETED